Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 7/20 | 0.64 |
| ▸ | NR1H2 | P55055 | 7/20 | 0.64 |
| ▸ | NR1H3 | Q13133 | 7/20 | 0.64 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | SLC16A3 | O15427 | 6/20 | 0.33 |
| ▸ | SLC16A1 | P53985 | 5/20 | 0.33 |
| ▸ | PRKDC | P78527 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | RORB | Q92753 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.31 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3473365 | 0.89 | RXRA (0.67) | RXRANR1H2NR1H3TGFBR1SLC16A3 | |
| SCHEMBL3472294 | 0.86 | RXRA (0.64) | RXRANR1H2NR1H3TGFBR1SLC16A3 | |
| SCHEMBL3472371 | 0.86 | RXRA (0.61) | RXRANR1H2NR1H3TGFBR1SLC16A3 | |
| SCHEMBL3475217 | 0.85 | RXRA (0.59) | RXRANR1H2NR1H3TGFBR1 | |
| SCHEMBL3471068 | 0.85 | RXRA (0.63) | RXRANR1H2NR1H3TGFBR1SLC16A3 | |
| SCHEMBL3471899 | 0.85 | RXRA (0.69) | RXRANR1H2NR1H3TGFBR1SLC16A3 | |
| SCHEMBL3477797 | 0.85 | RXRA (0.63) | RXRANR1H2NR1H3TGFBR1SLC16A3 | |
| SCHEMBL3471639 | 0.84 | RXRA (0.64) | RXRANR1H2NR1H3TGFBR1SLC16A3 | |
| SCHEMBL3471648 | 0.84 | RXRA (0.59) | RXRANR1H2NR1H3TGFBR1SLC16A3 | |
| SCHEMBL3473199 | 0.84 | RXRA (0.61) | RXRANR1H2NR1H3TGFBR1SLC16A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | claimed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100130617-A1 | ETHANOLAMINE MODULATORS OF NMDA RECEPTOR AND MUSCARINIC ACETYLCHOLINE RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| WO-2007002559-A1 | PYRAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130617-A1 | ETHANOLAMINE MODULATORS OF NMDA RECEPTOR AND MUSCARINIC ACETYLCHOLINE RECEPTOR | CHRM3, CHRM5, CHRM4 | RXRA 505/4885NR1H2 335/4885NR1H3 321/4885 |
| US-20100331295-A1 | MODULATORS OF LXR | NR1H2, NR1H3, NR1H4 | RXRA 18/4885NR1H2 1/4885NR1H3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.